CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Technologies Single and combination therapy with photodynamic therapy using verteporfin (V-PDT); anti-vascular endothelial growth factor (anti-VEGF) therapies, including pegaptanib, ranibizumab, and bevacizumab; and steroids or analogues, anecortave acetate and triamcinolone. Condition Adults 40 years of age or older with neovascular age-rela...